Drug Sponsors

Recipharm, Astimex form development and manufacturing collaboration

Friday, October 12, 2012 11:58 AM

Recipharm, a Swedish contract development and manufacturing organization, and Astimex Pharma, a Swedish pharmaceutical company, have formed a collaboration agreement for the development and manufacture of a pharmaceutical product.

More... »

GSK announces initiatives to advance openness and collaboration for global health challenges

Friday, October 12, 2012 11:04 AM

Global healthcare company GlaxoSmithKline has announced new measures to further advance its commitment towards greater openness, transparency and collaboration, designed to help develop new solutions for the world’s most serious health challenges.

More... »

ImaginAb, Lundbeck to collaborate in neurodegeneration

Wednesday, October 10, 2012 12:49 PM

ImaginAb, an Inglewood, Calif.-based clinical-stage company developing in vivomolecular imaging agents, has entered into a collaboration and commercialization agreement with Lundbeck, an international pharmaceutical company, on a novel central nervous system (CNS) target in order to explore the use of re-engineered antibodies to accelerate the blood-brain barrier (BBB) transport of biologics.

More... »

QRxPharma inks strategic collaboration with Paladin Labs

Wednesday, October 10, 2012 11:31 AM

QRxPharma, a commercial-stage specialty pharmaceutical company based in Bedminster, N.J., signed a licensing agreement with Paladin Labs, specialty pharmaceutical company based in Montreal, for the Canadian commercialization rights to Moxduo, a patented, immediate-release formulation of morphine and oxycodone. 

More... »

Amarantus, RBCC target NuroPro Parkinson's diagnostic for joint venture

Wednesday, October 10, 2012 11:03 AM

Amarantus BioSciences, a Sunnyvale, Calif.-based biotech focused on brain-related disorders including Parkinson's disease and traumatic brain injury (TBI), and Rainbow Coral (RBCC), a biotech subsidiary Rainbow BioSciences, have selected NuroPro, Amarantus' Parkinson's disease blood test in development, as the target product candidate for the proposed joint venture.

More... »

Takeda to acquire LigoCyte Pharmaceuticals

Friday, October 5, 2012 02:31 PM

Osaka, Japan-based Takeda Pharmaceutical’s wholly-owned subsidiary Takeda America Holdings will acquire LigoCyte Pharmaceuticals of Bozeman, Mont., for an upfront payment of $60 million, with future contingent consideration based on the progress of development projects.

More... »

KaloBios files registration statement for proposed IPO

Friday, October 5, 2012 02:25 PM

South San Francisco-based KaloBios Pharmaceuticals has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.

More... »

CollabRx partners with Life Technologies in molecular diagnostics

Friday, October 5, 2012 08:00 AM

CollabRx, a provider of cloud-based expert systems to inform health care decision-making, has formed a multi-year partnership agreement with Life Technologies, global biotechnology tools company for development and commercialization of CollabRx technology and content resources to be used in conjunction with Life Technologies' global cancer diagnostics development and its laboratory developed test services business.

More... »

Takeda, Advinus initiated multi-year drugs discovery collaboration

Thursday, October 4, 2012 02:19 PM

Takeda Pharmaceutical, a Japanese research-based pharmaceutical company, and Advinus Therapeutics, a privately held research-based pharmaceutical company based in India, have entered into an agreement to initiate a three-year discovery collaboration focused on novel targets for major therapeutic areas, including inflammation, CNS and metabolic diseases.

More... »

Epizyme earns $4M in milestones from GSK for novel HMT therapeutics

Thursday, October 4, 2012 11:52 AM

Epizyme, a pharmaceutical company focused personalized therapeutics for cancer, received a $4 million milestone payments from collaborator GlaxoSmithKline based on the achievement of pre-clinical milestones.

More... »